A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer.

Cristina P RodriguezQian Vicky WuJenna VoutsinasJonathan R FrommXiuyun JiangVenu G PillarisettySylvia M LeeRafael Santana-DavilaBernardo GoulartChristina S BaikLaura Q M ChowKeith EatonRenato Martins

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

This combination demonstrated activity in HN, with fewer responses in SGC. Toxicities were higher than reported with pembrolizumab alone.

Keyphrases

squamous cell
advanced non small cell lung cancer
squamous cell carcinoma
small cell lung cancer
high grade
open label
clinical trial
epidermal growth factor receptor
placebo controlled
double blind
childhood cancer